Isoquinolinone Rho kinase inhibitors
US8809326B2 · kind B2 · utility
38Cited by
24References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2007 |
| Grant date | Aug 19, 2014 |
| Priority date | — |
| Expiry date | Jul 24, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.